2556-42-5

Basic information

• Product Name: tetrapropylthioperoxydicarbamic acid
• Synonyms: Disulfide, bis(dipropylthiocarbamoyl); 4-04-00-00491 (Beilstein Handbook Reference); AI3-14919; BRN 1714218; Tetra-n-propylthiuram disulfide; Tetrapropylthiuram disulphide; Thiuram, tetrapropyl-, disulfide; tetra-n-Propylthiuramdisulfide; Tetrapropylthioperoxydicarbamic acid; Thioperoxydicarbonic diamide (((H2N)C(S))2S2), tetrapropyl-; 1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetrapropane
• CAS NO: 2556-42-5
• Molecular Formula: C₁₄H₂₈N₂S₄
• Molecular Weight: 352.6455
• EINECS: 219-871-5
• Mol File: 2556-42-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 425.8°C at 760 mmHg
• Flash Point: 211.3°C
• Density: 1.13g/cm³
• Vapor Pressure: 1.86E-07mmHg at 25°C
• Refractive Index: 1.587
• CAS DataBase Reference: tetrapropylthioperoxydicarbamic acid(CAS DataBase Reference)
• NIST Chemistry Reference: tetrapropylthioperoxydicarbamic acid(2556-42-5)
• EPA Substance Registry System: tetrapropylthioperoxydicarbamic acid(2556-42-5)

Safety Data

• Hazardous Substances Data: 2556-42-5(Hazardous Substances Data)

Upstream product

• 4143-50-4 N,N'-dipropyldithiocarbamate sodium 
• 75-15-0 carbon disulfide 
• 142-84-7 di-n-propylamine 

Downstream Products

• 55947-00-7 C₁₃H₂₆N₂S₂ 
• 14354-08-6 copper(II) di-n-propyldithiocarbamate 
• 27086-19-7 N,N-dipropylcarbamoyl chloride 

Relevant articles and documents

Bis(dipropylthiocarbamoyl) disulfide

In the title compound, C14H28N2S4, the two dithiocarbamate groups, which are perpendicular to each other, are bridged by an S-S bond. The C-N bonds in the dithiocarbamate groups show partial double-bond character.

Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes

Fructose-1,6-bisphosphatase (FBPase), as a key rate-limiting enzyme in the gluconeogenesis (GNG) pathway, represents a practical therapeutic strategy for type 2 diabetes (T2D). Our previous work first identified cysteine residue 128 (C128) was an important allosteric site in the structure of FBPase, while pharmacologically targeting C128 attenuated the catalytic ability of FBPase. Herein, ten approved cysteine covalent drugs were selected for exploring FBPase inhibitory activities, and the alcohol deterrent disulfiram displayed superior inhibitory efficacy among those drugs. Based on the structure of lead compound disulfiram, 58 disulfide-derived compounds were designed and synthesized for investigating FBPase inhibitory activities. Optimal compound 3a exhibited significant FBPase inhibition and glucose-lowering efficacy in vitro and in vivo. Furthermore, 3a covalently modified the C128 site, and then regulated the N125–S124–S123 allosteric pathway of FBPase in mechanism. In summary, 3a has the potential to be a novel FBPase inhibitor for T2D therapy.

Combinations for the treatment of fungal infections

The invention features methods and compositions for treating a patient diagnosed with, or at risk for developing, a fungal infection.